SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
SUPERNUS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$39.84+1.96 (+5.17%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
SUPERNUS PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $165.71M | $150.75M | $158.01M | $168.54M | $158.00M | $141.99M | $166.40M | $170.30M | $162.54M | $138.46M | $156.02M | $149.00M | 75.6% | +4.9% |
| Qelbree | $89.24M | $77.84M | $80.95M | $81.42M | $77.55M | $64.75M | $74.42M | $62.36M | $59.40M | $45.10M | $46.35M | $37.08M | 40.7% | +15.1% |
| GOCOVRI | $37.53M | $35.24M | $38.63M | $40.85M | $36.66M | $30.69M | $36.90M | $35.66M | $31.70M | $26.56M | $31.99M | $32.89M | 17.1% | +2.4% |
| Collaboration revenue (ZURZUVAE) | $35.35M | $27.64M | $32.83M | $20.16M | $0 | $0 | $0 | $0 | – | – | – | – | 16.1% | – |
| Royalty, licensing, and other revenues | $18.00M | $29.31M | $20.73M | $3.40M | $7.46M | $7.84M | $7.76M | $5.39M | $5.79M | $5.18M | $8.30M | $4.88M | 8.2% | +141.3% |
| ONAPGO | $13.55M | $8.38M | $8.84M | $6.81M | $1.60M | $0 | $0 | $0 | $0 | – | – | – | 6.2% | +744.5% |
| Oxtellar XR | $8.78M | $7.42M | $6.85M | $12.02M | $11.64M | $10.20M | $13.20M | $29.81M | $29.52M | $26.94M | $31.05M | $29.64M | 4.0% | -24.5% |
| Trokendi XR | $8.41M | $9.48M | $8.38M | $10.04M | $11.19M | $12.80M | $14.81M | $15.32M | $17.09M | $15.99M | $19.60M | $20.63M | 3.8% | -24.9% |
| APOKYN | $6.32M | $7.73M | $9.59M | $10.39M | $12.82M | $14.98M | $20.12M | $19.87M | $17.30M | $16.65M | $18.76M | $21.51M | 2.9% | -50.7% |
| Other | $1.88M | $4.67M | $4.77M | $7.03M | $6.53M | $8.58M | $6.96M | $7.30M | $7.54M | $7.21M | $8.27M | $7.26M | 0.9% | -71.2% |
| Royalty and licensing revenues | – | – | – | – | – | – | – | – | – | – | $8.30M | $4.88M | – | – |
| Royalty and licensing revenues | – | – | – | – | – | – | – | – | – | $5.18M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Supernus Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.